Literature DB >> 23635520

Adrenal function in preterm infants undergoing patent ductus arteriosus ligation.

Afif EL-Khuffash1, Patrick J McNamara, Anie Lapointe, Amish Jain.   

Abstract

BACKGROUND: Targeted milrinone treatment for low left ventricular output (LVO) reduces the incidence of acute cardiorespiratory instability following ligation of patent ductus arteriosus (PDA) in preterm infants. Despite this, some infants continue to experience postoperative deterioration. Adrenal insufficiency related to prematurity has been postulated as a possible mechanism.
OBJECTIVES: To describe adrenal function in premature infants undergoing PDA ligation and to investigate its association with pre- and postoperative clinical and echocardiography-derived indices of disease severity.
METHODS: A retrospective cohort study was conducted over a 2-year period on infants who underwent PDA ligation and had preoperative adrenocorticotropic hormone (ACTH) stimulation. All infants were screened by echocardiography for low LVO at 1 h after surgery and treated with intravenous milrinone if LVO <200 ml/kg/min. The primary outcome evaluated was low LVO at 1 h after surgery. Secondary outcomes included hypotension and oxygenation and ventilation failure occurring within 24 h.
RESULTS: A total of 35 infants at a median gestation of 25.4 (24.5-26.4) weeks and weight at birth of 700 (600-810) g were included. Baseline median cortisol measured preoperatively was 202 (137-403) nmol/l. Following the ACTH stimulation test, 3 infants had cortisol ≤500 nmol/l while 15 had ≤750 nmol/l. There was no association seen between any cortisol value and low LVO postoperatively. Post-ACTH cortisol ≤750 nmol/l was significantly associated with hypotension (p = 0.03) and oxygenation (p = 0.04) and ventilation (p = 0.008) failure. Receiver-operator characteristic curve showed a high predictive value of post-ACTH cortisol for all clinical outcomes.
CONCLUSIONS: Post-ACTH cortisol (≤750 nmol/l) may be associated with clinical indices of postoperative cardiorespiratory instability. Relative adrenal insufficiency may play a role in the etiology of post-PDA ligation hemodynamic and respiratory instability.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23635520     DOI: 10.1159/000350017

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  5 in total

1.  Hypotension following patent ductus arteriosus ligation: the role of adrenal hormones.

Authors:  Ronald I Clyman; Andrea Wickremasinghe; T Allen Merritt; Tabitha Solomon; Patrick McNamara; Amish Jain; Jaideep Singh; Alison Chu; Shahab Noori; Krishnamurthy Sekar; Pascal M Lavoie; Joshua T Attridge; Jonathan R Swanson; Maria Gillam-Krakauer; Jeff Reese; Sara DeMauro; Brenda Poindexter; Sue Aucott; Monique Satpute; Erika Fernandez; Richard J Auchus
Journal:  J Pediatr       Date:  2014-03-15       Impact factor: 4.406

2.  Catecholamine-resistant hypotension and myocardial performance following patent ductus arteriosus ligation.

Authors:  S Noori; P McNamara; A Jain; P M Lavoie; A Wickremasinghe; T A Merritt; T Solomon; K Sekar; J T Attridge; J R Swanson; M Gillam-Krakauer; J Reese; B B Poindexter; M Brook; R J Auchus; R I Clyman
Journal:  J Perinatol       Date:  2014-08-14       Impact factor: 2.521

3.  The impact of a dedicated patent ductus arteriosus ligation team on neonatal health-care outcomes.

Authors:  M H F Resende; K More; D Nicholls; J Ting; A Jain; P J McNamara
Journal:  J Perinatol       Date:  2016-01-14       Impact factor: 2.521

Review 4.  Patent ductus arteriosus in preterm infants: do we have the right answers?

Authors:  Hesham Abdel-Hady; Nehad Nasef; Abd Elazeez Shabaan; Islam Nour
Journal:  Biomed Res Int       Date:  2013-12-23       Impact factor: 3.411

Review 5.  Circulatory Insufficiency and Hypotension Related to the Ductus Arteriosus in Neonates.

Authors:  Danielle R Rios; Soume Bhattacharya; Philip T Levy; Patrick J McNamara
Journal:  Front Pediatr       Date:  2018-03-15       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.